Literature DB >> 25355247

Thyroglobulin measurement by highly sensitive assays: focus on laboratory challenges.

Luca Giovanella, Ulla Feldt-Rasmussen, Frederik A Verburg, Stephan K Grebe, Mario Plebani, Penelope M Clark.   

Abstract

Differentiated thyroid cancer (DTC) is the most common endocrine cancer and its incidence has increased in recent decades. The initial treatment consists of total thyroidectomy followed by ablation of thyroid remnants by radioiodine in most cases. As thyroid cells are the only source of thyroglobulin (Tg), circulating Tg serves as a biochemical marker of persistent or recurrent disease in the follow-up of DTC. Due to the suboptimal clinical detection rate of older Tg assays endogenous or exogenous thyrotropin (TSH) stimulations are recommended for unmasking occult disease. However, the development of new Tg assays with improved analytical sensitivity and precision at low concentrations now allows detection of very low Tg concentrations, reflecting minimal amounts of thyroid tissue, even without the need for TSH stimulation. Even if the use of these assays still has not found its way in current clinical guidelines, such assays are now increasingly used in clinical practice. As serum Tg measurement is a technically challenging assay and criteria to define a 'highly sensitive' assay may be different, a good knowledge of the technical difficulties and interpretation criteria is of paramount importance for both clinical thyroidologists, laboratory physicians and scientists involved in the care of DTC patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25355247     DOI: 10.1515/cclm-2014-0813

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  12 in total

1.  Thyroglobulin antibody resolution after total thyroidectomy for cancer.

Authors:  Jimmy Xu; Ryan Bergren; David Schneider; Herbert Chen; Rebecca S Sippel
Journal:  J Surg Res       Date:  2015-04-02       Impact factor: 2.192

2.  Postoperative serum thyroglobulin and neck ultrasound to drive decisions about iodine-131 therapy in patients with differentiated thyroid carcinoma: an evidence-based strategy?

Authors:  Luca Giovanella; Anca M Avram; Jerome Clerc; Elif Hindié; David Taïeb; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-30       Impact factor: 9.236

3.  Thyroglobulin (Tg) Testing Revisited: Tg Assays, TgAb Assays, and Correlation of Results With Clinical Outcomes.

Authors:  Brian C Netzel; Stefan K G Grebe; B Gisella Carranza Leon; M Regina Castro; Penelope M Clark; Andrew N Hoofnagle; Carole A Spencer; Adina F Turcu; Alicia Algeciras-Schimnich
Journal:  J Clin Endocrinol Metab       Date:  2015-06-16       Impact factor: 5.958

4.  Characterization of a new highly sensitive immunometric assay for thyroglobulin with reduced interference from autoantibodies.

Authors:  Marianne Nordlund Broughton; Ragnhild Nome; Ingvill Sandven; Elisabeth Paus; Trine Bjøro
Journal:  Tumour Biol       Date:  2015-12-22

5.  Serum thyroglobulin reference intervals in regions with adequate and more than adequate iodine intake.

Authors:  Zhaojun Wang; Hanyi Zhang; Xiaowen Zhang; Jie Sun; Cheng Han; Chenyan Li; Yongze Li; Xiaochun Teng; Chenling Fan; Aihua Liu; Zhongyan Shan; Chao Liu; Jianping Weng; Weiping Teng
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

6.  Definition of the upper reference limit for thyroglobulin antibodies according to the National Academy of Clinical Biochemistry guidelines: comparison of eleven different automated methods.

Authors:  F D'Aurizio; P Metus; A Ferrari; B Caruso; R Castello; D Villalta; A Steffan; K Gaspardo; F Pesente; N Bizzaro; E Tonutti; S Valverde; C Cosma; M Plebani; R Tozzoli
Journal:  Auto Immun Highlights       Date:  2017-06-19

7.  Serum thyroglobulin evaluation on LC-MS/MS and immunoassay in TgAb-positive patients with papillary thyroid carcinoma.

Authors:  Eijun Nishihara; Yoshitaka Hobo; Akira Miyauchi; Yasuhiro Ito; Miyoko Higuchi; Mitsuyoshi Hirokawa; Mitsuru Ito; Shuji Fukata; Mitsushige Nishikawa; Takashi Akamizu
Journal:  Eur Thyroid J       Date:  2022-01-19

8.  Thyroglobulin doubling time offers a better threshold than thyroglobulin level for selecting optimal candidates to undergo localizing [18F]FDG PET/CT in non-iodine avid differentiated thyroid carcinoma.

Authors:  Domenico Albano; Mark Tulchinsky; Francesco Dondi; Angelica Mazzoletti; Davide Lombardi; Francesco Bertagna; Raffaele Giubbini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-08-13       Impact factor: 9.236

Review 9.  Hormone Immunoassay Interference: A 2021 Update.

Authors:  Khaldoun Ghazal; Severine Brabant; Dominique Prie; Marie-Liesse Piketty
Journal:  Ann Lab Med       Date:  2022-01-01       Impact factor: 3.464

10.  The role of Tg kinetics in predicting 2-[18F]-FDG PET/CT results and overall survival in patients affected by differentiated thyroid carcinoma with detectable Tg and negative 131I-scan.

Authors:  Domenico Albano; Mark Tulchinsky; Francesco Dondi; Angelica Mazzoletti; Francesco Bertagna; Raffaele Giubbini
Journal:  Endocrine       Date:  2021-05-20       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.